Blockchain - The Game Changer in the Optimization and Efficacy of Clinical Trials Webinar

Blockchain - The Game Changer in the Optimization and Efficacy of Clinical Trials Webinar

Presented by IEEE Standards Association Corporate Membership Program

11 October 2017
2:00 p.m. EDT

View All Webinars & Panel Discussions


On 11 October 2017, join IEEE Standards Association (IEEE-SA) Corporate Membership Program for an exclusive blockchain webinar. Data sharing, data privacy, and patient recruitment in clinical trials are significant challenges for clinical research. There is a clear competitive relationship between data sharing and privacy where both must be satisfied:

  1. The need for data-sharing amongst stakeholders (researchers, healthcare providers, and regulators); and
  2. The need for patient privacy and confidentiality have created an unsustainable environment for existing legacy platforms that cannot ensure data integrity.

Blockchain has made significant strides in the financial and healthcare sectors offering a new perspective and platform for data management, distribution, and verification in this global data-sharing economy. This webinar will address the potential applications for blockchain applications within the clinical trials process.

Key learning objectives include:

  • Understanding how blockchain applications will optimizing the clinical trials process from patient engagement through data authentication.
  • Evaluating the differences between public vs. private and permissioned blockchains for ensuring data patient and data privacy while having the ability to share, audit, and append an immutable single data source.
  • What is the difference between blockchain and centralized databases as it relates to security and data-sharing capabilities?
  • What are some of the regulatory considerations when employing a blockchain solution?
  • Where and how can blockchain create a more inclusive and effective patient engagement program?
  • What are some of the unresolved issues that must be addressed to move towards adoption?
  • Plus, usage studies and latest updates on industry’s move towards blockchain applications.



Robert Barkovich Robert Barkovich, CEO & Founder, Health Linkages

Robert is a product leader with more than 15 years of experience on the software and IT side of healthcare and life sciences. Robert is currently the CEO of Health Linkages Inc., a company focused on solving the data provenance problem in the healthcare and life sciences industries. Health Linkages uses a combination of blockchain and big data technologies to allow organizations to trust, protect and share their data.  Robert has a Ph.D. in Chemistry and Biochemistry from UCLA.  His career includes positions Deloitte, Thermo Fisher Scientific, Affymetrix and Amersham Pharmacia Biotech. He has also worked with and consulted for many startups and larger companies.

Edward Bukstel Edward Bukstel, CEO, Clinical Blockchain

Mr. Bukstel has 30 years of clinical data integration, data security, and communications experience. He has successfully licensed systems and services to companies, including international pharmaceutical and managed care organizations. Mr. Bukstel was a founding member of the ASTM E1238 Standard that became integrated into HL7. He has been a national speaker on electronic data interchange and has been a guest lecturer at The Wharton Business School. Mr. Bukstel has written extensively on Blockchain and Healthcare and founded Clinical Blockchain LLC in 2016 to address Patient – Doctor Messaging on a Blockchain Platform.

Vladimir Petrovic, Clinical Biomarkers and Diagnostics, Amgen Vladimir Petrovic, Clinical Biomarkers and Diagnostics, Amgen

Vladimir Petrovic has earned his Ph.D. in Biochemistry and Molecular Genetics at the University of Illinois at Chicago. He has completed his postdoctoral training at Lurie Cancer Center of Northwestern University in Chicago focusing on molecular signaling in breast cancer. He joined Carbone Cancer Center at the University of Wisconsin in Madison as a staff scientist to further study oncogenic signaling and regulatory networks in human malignancies. He is currently a part of Clinical Biomarkers and Diagnostics group at Amgen’s San Francisco campus. His work revolves around Amgen’s oncology clinical trials, spanning several indications and therapeutic modalities. In addition, he collaborates with Amgen Ventures to bring blockchain oriented platforms to Amgen and identify startup companies that develop blockchain-based applications that integrate into clinical trial process.

Maria Palombini (Moderator), Director, Community and Initiative Development, IEEE-SA Maria Palombini (Moderator), Director, Community and Initiative Development, IEEE-SA

In 2017, Maria joined IEEE-SA with a directive build networks of tech innovators, researchers and corporate executives who share a common goal of developing standards to advance adoption of emerging technologies into their enterprise. Her work includes building a community of tech innovators, business executives, academics and industry advocates to educate on the benefits and challenges with blockchain while collaborating to develop standards to advance adoption. Her primary sectors of focus include pharma, health, energy, and agriculture. In parallel to her work in blockchain standards, she is project lead for IEEE-SA’s newest initiative, Digital Inclusion through Trust and Agency, a critical program focused on restoring dignity to digital citizen/identity for the global community including the underserved.

Maria currently holds an MBA from the Rutgers Graduate School of Business and a BA and BS from Rutgers College at Rutgers University, the State University of New Jersey. She is an accomplished leader and public speaker having presented at various industry events.